Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
First Claim
Patent Images
1. A system for treating drug-resistant tuberculosis, comprising:
- a pretreatment composition configured for intravenous administration, the pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide (DMSO);
a formulation comprising therapeutic agents dissolved in DMSO,wherein a concentration of the DMSO ranges from about 50% to about 95% in a total volume of about two to about six milliliters of the formulation,wherein the therapeutic agents are selected from three or more compounds selected from the group consisting of;
streptomycin, isoniazid, rifampicin, pyraziamide, and ethambutol; and
an inhalant device.
0 Assignments
0 Petitions
Accused Products
Abstract
Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.
-
Citations
10 Claims
-
1. A system for treating drug-resistant tuberculosis, comprising:
-
a pretreatment composition configured for intravenous administration, the pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide (DMSO); a formulation comprising therapeutic agents dissolved in DMSO, wherein a concentration of the DMSO ranges from about 50% to about 95% in a total volume of about two to about six milliliters of the formulation, wherein the therapeutic agents are selected from three or more compounds selected from the group consisting of;
streptomycin, isoniazid, rifampicin, pyraziamide, and ethambutol; andan inhalant device. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A kit for treating drug-resistant tuberculosis, the kit comprising:
-
a pretreatment composition configured for intravenous administration, the pretreatment composition comprising about 50 mg to about 60 mg dimethylsulfoxide (DMSO); a formulation comprising therapeutic agents dissolved in DMSO, wherein a concentration of the DMSO ranges from about 50% to about 95% in a total volume of about two to about six milliliters of the formulation, wherein the therapeutic agents are selected from three or more compounds selected from the group consisting of;
streptomycin, isoniazid, rifampicin, pyraziamide, and ethambutol;an inhalant device; and instructions for administering the formulation via the inhalant device at least three times daily.
-
Specification